The Aging Population Drives Growth In Colorectal Cancer Screening Demand: The Driving Engine Behind Colorectal Cancer Screening Market Evolution in 2025

Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

What Is the Expected CAGR for the Colorectal Cancer Screening Market Through 2025?
The market size of colorectal cancer screening has experienced significant growth lately. It's expected to rise from $15.61 billion in 2024 to $16.56 billion in 2025, boasting a compound annual growth rate (CAGR) of 6.0%. The upward trend during the historic period can be linked to factors such as the escalation in colorectal cancer cases, enhanced government-initiated awareness programs, an increase in the elderly population, burgeoning adoption of colonoscopy, and better insurance coverage.

What's the Projected Size of the Global Colorectal Cancer Screening Market by 2029?
In the coming years, a robust expansion is anticipated in the colorectal cancer screening market. It is projected to reach a worth of $20.87 billion in 2029 with a compound annual growth rate (CAGR) of 6.0%. This predicted growth in the forecast period is largely due to the adoption of non-invasive screening procedures, the augmentation of home-based screening tests, growing obesity rates, the upswing in value-based healare adoption, and escalating public-private collaborations. Anticipated trends throughout the forecast period include the addition of AI into screening and diagnostic processes, the widening of screening guidelines to include younger demographics, an increase in utilisation of genomic testing for cancer susceptibility, the proliferation of mobile health (mHealth) platforms, and strategic alliances between pharmaceutical and diagnostics companies.

View the full report here:
https://www.thebusinessresearchcompany.com/report/colorectal-cancer-screening-global-market-report

Top Growth Drivers in the Colorectal Cancer Screening Industry: What's Accelerating the Market?
The surge in the elderly population is forecasted to spur the expansion of the colorectal cancer screening market. The term elderly population depicts a demographic shift in which the fraction of individuals aged 65 years and above escalates in comparison to the active workforce, generally due to extended lifespan and falling birth rates. The elderly population's growth owes to longer lifespans and reduced birth rates, leading to a greater percentage of senior citizens in the worldwide population. Colorectal cancer screening plays a crucial role in catering to the growing needs of the expanding elderly population by facilitating early diagnosis and preventive strategies that tackle the heightened risk of cancer in senior citizens and improve their overall health conditions. For example, as per the information revealed by the Population Reference Bureau (PRB), a nonprofit research organization based in the US, the count of Americans aged 65 and beyond is projected to go up from 58 million in 2022 to 82 million by 2050, which indicates a 47% increase, and their fraction of the entire population is expected to rise from 17% to 23%. Thus, the burgeoning elderly population is boosting the progression of the colorectal cancer screening market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=19008&type=smp

What Trends Will Shape the Colorectal Cancer Screening Market Through 2029 and Beyond?
In the colorectal cancer screening market, leading businesses are concentrating on creating new solutions like non-invasive multi-target stool RNA colorectal cancer screening tests. These innovative solutions are aimed at providing a convenient and efficient method for the early identification of colorectal cancer, enhancing patient results and promoting widespread participation in screening. The non-invasive multi-target stool RNA colorectal cancer tests use RNA markers obtained from stool samples to identify the existence of colorectal cancer or precancerous abnormalities, thus offering a non-surgical approach for early detection. For example, in May 2024, Geneoscopy Inc., a life sciences firm from the US, declared that the U.S. Food and Drug Administration (FDA) has given approval to ColoSense. ColoSense utilizes RNA biomarkers in a non-invasive, stool-based screening which displayed 93% accuracy in identifying colorectal cancer and 45% accuracy in detecting advanced adenomas. The importance of ColoSense lies not only in its remarkable accuracy, particularly in younger demographics, but also in its potential to raise screening participation rates by providing a less invasive alternative to conventional methods.

What Are the Main Segments in the Colorectal Cancer Screening Market?
The colorectal cancer screeningmarket covered in this report is segmented -

1) By Type: Stool-Based, Fecal Immunochemical Test (FIT), Fecal Occult Blood Test (FOBT), Stool Deoxyribonucleic Acid (DNA) Test, Colonoscopy, Other Types
2) By Age Group: Below 50 Years, 50-64 Years, Above 65 Years
3) By End User: Hospitals And Clinics, Clinical Laboratories, Diagnostic Imaging Centers, Other End-Users

Subsegments:
1) By Stool-Based Tests: Stool-Based Tests
2) By Fecal Immunochemical Test (FIT): High-Sensitivity FIT, Low-Sensitivity FIT
3) By Fecal Occult Blood Test (FOBT): Guaiac FOBT, Immunochemical FOBT
4) By Stool Deoxyribonucleic Acid (DNA) Test: Multi-Target Stool DNA Test, Single-Target Stool DNA Test
5) By Colonoscopy: Diagnostic Colonoscopy, Therapeutic Colonoscopy
6) By Other Types: Virtual Colonoscopy, Flexible Sigmoidoscopy, Capsule Endoscopy

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=19008&type=smp

Which Top Companies are Driving Growth in the Colorectal Cancer Screening Market?
Major companies operating in the colorectal cancer screening market are F. Hoffmann-La Roche AG, Thermo Fisher Scientific Inc., Abbott Laboratories, Medtronic plc, Siemens Healthineers, FUJIFILM Holdings Corporation, GE Healare, Boston Scientific Corporation, Olympus Corporation, Hologic Inc., bioMérieux SA, QuidelOrtho Corporation, Sysmex Corporation, QIAGEN N.V., Exact Sciences Corporation, Guardant Health Inc., Eiken Chemical Co. Ltd., HemoCue AB, Clinical Genomics Inc., Polymedco LLC, Hemosure Inc., Geneoscopy Inc., Novigenix SA

Which Regions Will Dominate the Colorectal Cancer Screening Market Through 2029?
North America was the largest region in the colorectal cancer screening market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the colorectal cancer screening market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=19008

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Speak With Our Expert:
Saumya Sahay
Europe - +44 7882 955267,
Asia: +91 88972 63534,
Americas - +1 310-496-7795 or
Email:saumyas@tbrc.info
Follow Us On:
• LinkedIn: https://in.linkedin.com/company/the-business-research-company

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.